GlassScriptPhysician profile
Michael Casey Maloney
NPI 1013971266
$3,130.22
in general payments reported to CMS, 2019-2025
15 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $48.87 · 2021: $157 · 2022: $556 · 2023: $670 · 2024: $559 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,255.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $623.04 | 2024-2025 | Xdemvy |
| Abbvie INC. | $507.59 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $322.65 | 2019-2024 | Acuvue |
| Rxsight INC | $271.11 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Alcon Vision LLC | $270.99 | 2020-2023 | Eysuvis |
| Ocular Therapeutix, INC. | $163.97 | 2022-2024 | Dextenza |
| Sun Pharmaceutical Industries INC. | $158.20 | 2024 | |
| Bausch & Lomb Americas INC. | $137.56 | 2022-2025 | Miebo, Scoutpro Osmolarity System |
| Aerie Pharmaceuticals, INC. | $121.41 | 2019-2021 | |
| Glaukos Corporation | $120.69 | 2023 | Photrexa Cross-Linking Kit, Istent Trabecular Micro-Bypass Stent System, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Novartis Pharmaceuticals Corporation | $114.28 | 2019-2023 | |
| Coopervision INC. | $110.77 | 2020-2022 | |
| Apellis Pharmaceuticals, INC. | $106.49 | 2023 | Syfovre |
| Harrow Eye, LLC | $62.71 | 2024-2025 | Vevye |
| Allergan, INC. | $38.76 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Maloney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.